Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.

Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed ...

As of July 1, CVS dropped Zepbound from preferred coverage for those covered by its pharmacy benefit manager, Caremark. Novo Nordisk A/S's Wegovy, a semaglutide injectable medicine, is now the ...

Some consumers are taking smaller than standard doses of GLP-1s—the popular class of weight-loss and diabetes drugs that include Ozempic, Wegovy, and Zepbound—or spacing out doses longer than ...

The price of weight loss drugs is falling. Wegovy and Zepbound, which both sell for a list price of more than $1,000 a month, have long been out of reach for people without insurance or whose ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500.

Wegovy and Zepbound prices fall, but access to the obesity drugs still isn’t guaranteed The medications Wegovy and Zepbound still amount to around $500 per month for those without insurance ...

While Zepbound leads today, the next potential rally may be sparked by Orforglipron, Eli Lilly's small-molecule oral GLP-1. Phase 3 obesity data is expected in the third quarter, with a launch ...

Even on Zepbound, I don’t necessarily wake up completely ready to start the day, but it’s way easier than it was before. I get up at 5:30 or 6 a.m. It’s nice to be up when the sun is up.

Zepbound’s results were relatively unchanged year over year, though the number of U.S. patients starting on the medication in 2023 was limited since it did not launch until November of that year.

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. What is gestational diabetes?